{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "3381047",
  "DateCompleted": {
    "Year": "1988",
    "Month": "07",
    "Day": "28"
  },
  "DateRevised": {
    "Year": "2006",
    "Month": "11",
    "Day": "15"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "fre"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0035-3787",
      "JournalIssue": {
        "Volume": "144",
        "Issue": "2",
        "PubDate": {
          "Year": "1988"
        }
      },
      "Title": "Revue neurologique",
      "ISOAbbreviation": "Rev Neurol (Paris)"
    },
    "ArticleTitle": "[Cerebral ischemic accidents and chronic disseminated intravascular coagulation of cancerous origin].",
    "Pagination": {
      "StartPage": "120",
      "EndPage": "124",
      "MedlinePgn": "120-4"
    },
    "Abstract": {
      "AbstractText": [
        "Cerebral infarcts in 3 patients revealed the presence of disseminated intravascular coagulation (DIVC) of cancerous origin before any clinical manifestations of the neoplasm. Neurologic manifestations of these consumption coagulopathies almost constantly produce a picture of diffuse encephalopathy, expression of disseminated microinfarcts; however, transient or constituted focalized ischemic accidents by occlusion of a medium sized artery are also possible, and this in the absence of non-bacterial thrombotic endocarditis. Biologic diagnosis of DIVC is not always simple, and screening tests (platelet count, prothrombin and fibrinogen levels) can remain within normal limits during chronic forms, as a result of a subjacent inflammatory syndrome, frequently associated with cancer. Two other specific serum tests are therefore of fundamental interest: assay of fibrin degradation products and tests for soluble complexes."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Unit\u00e9 d'Accidents Vasculaires C\u00e9r\u00e9braux, H\u00f4pital Lariboisi\u00e8re, UER Lariboisi\u00e8re-Saint Louis, Paris."
          }
        ],
        "LastName": "Woimant",
        "ForeName": "F",
        "Initials": "F"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Moulinier",
        "ForeName": "L",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Lecoz",
        "ForeName": "P",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Soria",
        "ForeName": "C",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Mikol",
        "ForeName": "J",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Cochan Priollet",
        "ForeName": "B",
        "Initials": "B"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Haguenau",
        "ForeName": "M",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "P\u00e9pin",
        "ForeName": "B",
        "Initials": "B"
      }
    ],
    "PublicationTypeList": [
      "Case Reports",
      "English Abstract",
      "Journal Article"
    ],
    "VernacularTitle": "Accidents ischemiques c\u00e9r\u00e9braux et coagulation intravasculaire diss\u00e9min\u00e9e chronique d'origine canc\u00e9reuse."
  },
  "MedlineJournalInfo": {
    "Country": "France",
    "MedlineTA": "Rev Neurol (Paris)",
    "NlmUniqueID": "2984779R",
    "ISSNLinking": "0035-3787"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Fibrin Fibrinogen Degradation Products"
    },
    {
      "RegistryNumber": "9001-26-7",
      "NameOfSubstance": "Prothrombin"
    },
    {
      "RegistryNumber": "9001-32-5",
      "NameOfSubstance": "Fibrinogen"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "complications"
      ],
      "DescriptorName": "Adenocarcinoma"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [
        "etiology"
      ],
      "DescriptorName": "Cerebral Infarction"
    },
    {
      "QualifierName": [
        "complications"
      ],
      "DescriptorName": "Cystadenoma"
    },
    {
      "QualifierName": [
        "blood",
        "etiology"
      ],
      "DescriptorName": "Disseminated Intravascular Coagulation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [
        "analysis"
      ],
      "DescriptorName": "Fibrin Fibrinogen Degradation Products"
    },
    {
      "QualifierName": [
        "analysis"
      ],
      "DescriptorName": "Fibrinogen"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [
        "complications"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [
        "complications"
      ],
      "DescriptorName": "Ovarian Neoplasms"
    },
    {
      "QualifierName": [
        "complications"
      ],
      "DescriptorName": "Pancreatic Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Platelet Count"
    },
    {
      "QualifierName": [
        "analysis"
      ],
      "DescriptorName": "Prothrombin"
    },
    {
      "QualifierName": [
        "complications"
      ],
      "DescriptorName": "Urinary Bladder Neoplasms"
    }
  ]
}